Back HCV Treatment

Boehringer Ingelheim Discontinues Faldaprevir, Halts HCV Drug Development

Boehringer Ingelheim has announced that it will discontinue development of its investigational hepatitis C virus (HCV) protease inhibitor faldaprevir, will withdraw pending approval requests, and will not proceed with further work in this area due to rapid changes in the hepatitis C treatment environment.

alt

Read more: